Leukemia Research Studies

< Back to Adolescent and Young Adult Cancer Research Studies Page

ALL Relapse / Refractory

20140106-CFZ008: Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

  • Conditions: Leukemia ALL Relapse, Adult - Leukemia ALL Relapse

PURPOSE: The purpose of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL). ARM INFORMATION: EXPERIMENT ...More

AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

  • Conditions: Leukemia ALL Relapse, Adult - Leukemia ALL Relapse

This randomized phase III trial compares how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, can block cancer ...More

AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

  • Conditions: Leukemia ALL Relapse, Adult - Leukemia ALL Relapse

PURPOSE: This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and ma ...More

CCTL019B2205J: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

  • Conditions: Leukemia ALL Relapse, Adult - Leukemia ALL Relapse

PURPOSE: This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL. DETAILED DESCRIPTION: This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 i ...More

CPX-MA-1201: A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies.

  • Conditions: Lymphoma Hodgkin Relapse, Lymphoma Non Hodgkin Relapse, Leukemia ALL Relapse, Leukemia AML Relapse, Adult - Leukemia AML Relapse, Adult - Leukemia ALL Relapse, Adult - Lymphoma Non Hodgkin Relapse, Adult - Lymphoma Hodgkin Relapse

  PURPOSE: The purpose of this study is to test the safety of a study drug called CPX-351. This drug has been tested in adults but not yet in children and adolescents. This study tests different doses of the drug to see which dose is safer in children and adolescents. Patients who have blood ca ...More

KTE-C19-104: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)

  • Conditions: Leukemia ALL Relapse, Adult - Leukemia ALL Relapse

PURPOSE: This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent ...More

T2012-002-MARQIBO: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia

  • Conditions: Leukemia ALL Relapse, Adult - Leukemia ALL Relapse

PURPOSE: This is a pilot study utilizing Marqibo® (vincristine sulfate liposome injection) combined with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute lymphoblastic leukemia (ALL). DETAILED DESCRIPTION: This study will utilize Marqibo® as a replacement for stan ...More

Contact Us

Contact us.

To learn more about available leukemia clinical trials, contact us at cancer@cchmc.org or 513-636-2799.